1 Overall, 901 (21%) patients
died during 1-year follow-up.
2 Subsequently, 332 patients
died during 16 102 person-years of follow-up.
3 al without an ICD after CF-LVAD implantation
died during 276.2 months of follow-up (mean time without
4 58 397 participants
died during 3 195 484 person-years of follow-up (average
5 A total of 6344 of 37 496 patients
died during 359 219 years of follow-up.
6 e likely to exercise and had a lower risk of
dying during 5-year follow-up, with exercise mediating t
7 se Database, 602 had incident cancer and 500
died during a follow-up period of up to 15 years (1995-2
8 4 [56.5%] were male), 80 individuals (15.9%)
died during a mean (SD) follow-up of 7.8 (1.5) years.
9 Of the 187 study participants, 46
died during a mean follow-up of 23.0 months.
10 9 had an echocardiogram and 217 of 739 (29%)
died during a mean follow-up of 4.2 years.
11 Among 434 PAD participants, 103 (24%)
died during a mean follow-up of 47.6 months.
12 Thirty-five (23.3%) patients
died during a mean follow-up period of 1,016 +/- 132 day
13 6 participants developed incident HF and 468
died during a mean follow-up period of 11.2 years.
14 vents occurred, and 151,441 (32.7%) patients
died during a mean follow-up period of 18.0 months.
15 Among 1727 HIV-positive PWID, 493 (28.5%)
died during a median 5.1 years (interquartile range, 2.1
16 788 patients (13.2%)
died during a median follow-up of 3.2 years, and 26.8% p
17 ne hundred twenty-three participants (27.8%)
died during a median follow-up of 4.7 years after the 2-
18 Ten patients
died during adulthood.
19 Overall, 3% and 4% of patients
died during bortezomib-based and nonbortezomib-based ind
20 ave implications for understanding how cells
die during certain stress conditions and how such cell d
21 experienced disease progression, one patient
died during chemotherapy, and all others had stable dise
22 s, but fewer of the activated CD8(+) T cells
died during contraction, generating a larger pool of mem
23 a material contribution: they spontaneously
die during copulation and are subsequently eaten by fema
24 nstead, male wasp larvae were more likely to
die during development.
25 is was delayed or failed, and 50% of embryos
died during development.
26 ears and older at treatment initiation, 2270
died during dialysis treatment (38.6/1000 person-years).
27 Of those younger than 5 years, 705
died during dialysis treatment (98.8/1000 person-years);
28 How trees
die during drought over multiple years remains largely u
29 majority of adult hippocampal newborn cells
die during early differentiation from intermediate proge
30 Because DSG2 knockouts
die during early embryogenesis, mice were prepared with
31 Almost all Armc5 knockout mice
died during early embryonic development, around 6.5 and
32 us kinase-dead mutations in Atm (Atm(KD/KD))
died during early embryonic development.
33 UBR4-deficient mice
die during embryogenesis and exhibit pleiotropic abnorma
34 together with a null allele of Bmp2 or Bmp4
die during embryogenesis with defects in ventral body wa
35 FBXL5-null mice
die during embryogenesis, although viability is restored
36 D1 prod double mutants
die during embryogenesis, exhibiting enhanced phenotypes
37 stemic inflammation, Ripk1(D325A/D325A) mice
died during embryogenesis.
38 Calr null mice
die during embryonic development, rendering indeterminat
39 her ENU mutation (or compound heterozygotes)
died during embryonic development at 9.5-14.5 days post
40 Most zooxanthellar phylotypes are
dying during expulsion upon release from the host.
41 ents engaged in exercise were less likely to
die during follow-up (hazard ratio, 0.50; 95% confidence
42 Xpert-negative patients were less likely to
die during follow-up.
43 Three donors
died during follow-up (0.6-4.9 years) as a result of the
44 Eight patients
died during follow-up (2 sudden unexpected and 6 noncard
45 g 2,315 participants diagnosed with CRC, 966
died during follow-up (413 from CRC and 176 from cardiov
46 Overall, 157 patients (3%)
died during follow-up (all-cause mortality, 11.2/1000 PY
47 18% required mechanical ventilation and 21%
died during follow-up (compared with 23% and 20%, respec
48 om the trial 240 days after enrolment and 12
died during follow-up (five in the intervention group; s
49 Two hundred eighty-six patients (52%)
died during follow-up (mean follow-up 4.8 yr).
50 Participants who
died during follow-up appeared to have profiles of multi
51 Overall, 42 patients (12.1%)
died during follow-up as a result of cancer progression.
52 Eight patients (11%)
died during follow-up because of nonaortic-related cause
53 One patient
died during follow-up due to noncardiac cause.
54 51 (16%) of the cohort
died during follow-up from study entry (10 years after c
55 s with type 1 diabetes mellitus, 1809 (5.5%)
died during follow-up over 10.4 years.
56 Four patients
died during follow-up with a 5-year survival rate 99.5%
57 Eight of 1132 participants
died during follow-up, 2 in the postpartum period.
58 Thirty-five patients (12.7%)
died during follow-up, 33 of whom had decompensated cirr
59 Among the 1470 patients who
died during follow-up, 87% had EOL care discussions, com
60 Seven patients with MHSs
died during follow-up, all due to PNETs, including 4 pat
61 Overall, 65 936 of the full sample
died during follow-up, and 22 152 died from heart diseas
62 6155 (8.8%) people with epilepsy
died during follow-up, at a median age of 34.5 (IQR 21.0
63 nts with documented EOL care discussions who
died during follow-up, discussions took place a median o
64 Of those, 48 patients
died during follow-up, including 18 because of CHF progr
65 l of 949 participants with colorectal cancer
died during follow-up, including 408 from colorectal can
66 the 2,548 colorectal cancer survivors, 1,074
died during follow-up, including 453 as a result of colo
67 Twelve patients (25%)
died during follow-up, mostly from heart failure (50%).
68 g 6,721 years of follow-up, 194 participants
died during follow-up, resulting in a crude mortality ra
69 A total of 15,138 men and 10,087 women
died during follow-up, which ended in 2008.
70 g the 27 619 current cigarette smokers, 4224
died during follow-up, with 1130 deaths attributed to CV
71 Overall, 59% of the women
died during follow-up, with 95% of deaths resulting from
72 e, 50-71 years]) in the study, 21123 (21.3%)
died during follow-up.
73 nts survived while all osteosarcoma patients
died during follow-up.
74 rders 0-3 months postpartum, and 96 of these
died during follow-up.
75 A total of 6,206 patients (9%)
died during follow-up.
76 A total of 118 patients
died during follow-up.
77 red retransplantation and 208 patients (22%)
died during follow-up.
78 A total of 117 (22%) patients
died during follow-up.
79 erapy group (two attributed to intervention)
died during follow-up.
80 Of 608 patients enrolled, 237
died during follow-up.
81 Overall, 45 (18.7%) patients
died during follow-up.
82 One patient (in the fluorouracil group)
died during follow-up.
83 Of the 444 patients with lung cancer, 318
died during follow-up.
84 e was 1.8 years (range, 0.1-78); 111 (10.2%)
died during follow-up.
85 ischemic cerebrovascular disease, and 3,807
died during follow-up.
86 Thirty patients (39.0%)
died during follow-up.
87 vents (2.6 per 100 patient-years), and 2,149
died during follow-up.
88 duals (age at baseline 18-109), of whom 5512
died during follow-up.
89 Fourteen patients
died during follow-up: 11 in the brachytherapy arm vs 3
90 A total of 3073 participants (6%)
died during follow-up; 78% of these deaths were attribut
91 n group and three in the peer-support group)
died during follow-up; these deaths were deemed unrelate
92 week) had a significantly increased risk of
dying during follow-up (HR=1.27, 95% CI 1.22-1.31).
93 e probability of developing cirrhosis and of
dying during follow-up using Cox proportional hazards mo
94 Odds of
dying during follow-up were 8.5-fold higher in patients
95 igands received prolonged IL-7 signaling and
died during homeostasis.
96 usion and 16 (17%) assigned to standard care
died during hospital stay.
97 06 and who did not have baseline dementia or
die during hospitalization (n = 164,661) were identified
98 ntly more likely than uninfected patients to
die during hospitalization after admission for AMI or st
99 ntly more likely than uninfected patients to
die during hospitalization after admission for AMI or st
100 develop ACLF and patients who did vs did not
die during hospitalization and within 30 days.
101 A small percentage of patients
die during hospitalization or shortly thereafter, and it
102 onfirmed underuse of echo among patients who
died during hospitalization for indications identified i
103 evere head or pelvic injuries, and those who
died during hospitalization were excluded.
104 nts admitted between 2011-2017 (n=2230), 17%
died during hospitalization, 32% were transferred to lon
105 4,119 patients (75.65%) in the steroid group
died during hospitalization, as compared with 4,403 pati
106 Two hundred seventeen patients (39%)
died during hospitalization, whereas another 69 patients
107 34 patients had microbiologic failure and 25
died during hospitalization.
108 Overall, 40 (17%) patients
died during hospitalization.
109 A total of 506 (18.5%) patients
died during hospitalization.
110 ad noncardiopulmonary complications and 5.4%
died during hospitalization.
111 east 1 antimicrobial agent, of whom 52 (14%)
died during hospitalization.
112 Eight (0.7%) RSV-infected study patients
died during hospitalization.
113 Sixty-six patients (38.1%)
died during hospitalization.
114 admitted to an intensive care unit, and 6.2%
died during hospitalization.
115 Approximately 14% of the ICC patients
died during hospitalization.
116 Although the likelihood of
dying during hospitalization was greater among patients
117 ieved in 153/180 (85%) patients and 27 (15%)
died during induction.
118 We excluded patients who
died during initial hospitalization or within 180 days o
119 alization, whereas another 69 patients (12%)
died during later follow-up.
120 These subjects were more likely to
die during long-term follow up (for severe PHT, adjusted
121 As billions of cells
die during mammalian embryogenesis and daily in adult or
122 n participants were separated into those who
died during Medicare follow-up and those who survived.
123 ronectin (FN) and osteopontin expression and
died during mesoderm development akin to FAK kinase-dead
124 odomain sites show loss of BMP4 function and
die during mid-embryogenesis.
125 knockdown increased the ratio of cells that
died during mitotic arrest and sensitized cancer cells t
126 lar to that at which endogenous interneurons
died during normal development.
127 standard arm patients were reported to have
died during passive follow-up.
128 Two patients
died during phase 1 and none during phase 2.
129 The adjusted odds of
dying during physical exertion were higher in men than i
130 in determining the fate of cells to live or
die during physiological processes such as embryonic dev
131 Two patients
died during postoperative therapy, one from infection (a
132 (50.8%) of the women of known HIV status who
died during pregnancy or post partum were HIV infected.
133 a systematic review of the relative risk of
dying during pregnancy for HIV-positive women compared w
134 ere alive at the outset of the NVVLS, and 81
died during recruitment; 1450 of the remaining 1839 (78.
135 For patients at a different hospital, 13.7%
died during rehospitalization versus 11.1% who died at t
136 hese data demonstrate that mice predicted to
die during sepsis have no significant lung injury.
137 b group (cause of death unknown; the patient
died during sleep).
138 plantation (15/142 versus 1/147; P<0.001) or
die during study follow-up period (7 versus 0; P=0.007).
139 Eight patients (4.2%) receiving ET-B
died during study or within 30 days of end of treatment.
140 Among 375,629 patients, 107,634
died during study period, of which 54,759 (50.87%) death
141 ients survived the FT procedure, one patient
died during subsequent revisions procedures for sepsis.
142 notified with TB over the study period, <1%
died during TB treatment and 89.5% were cured or complet
143 uring the inflammatory phase are destined to
die during termination of the immune response.
144 insights, it is still unclear how RPE cells
die during the course of the disease.
145 al, 1.41-12.6, P = .01), were more likely to
die during the first 8 weeks of remission induction ther
146 In nature, most juveniles
die during the first dry season, so that their harvest j
147 ing graft as compared with those who did not
die during the follow-up period (TNF-alpha: median, 1.92
148 tervention, 50 (79%) expected the patient to
die during the hospitalization and 58 (92%) expected the
149 and 36.7 times, respectively, more likely to
die during the neonatal period.
150 well as severe polycystic kidney disease and
die during the neonatal period.
151 presence of suicidal ideation with intent to
die during the past week and/or a suicide attempt within
152 e polycomb group gene member Yin-Yang1 (YY1)
die during the peri-implantation stage.
153 Casp8(C362A/C362A)Mlkl(-/-) mice
die during the perinatal period(5), whereas Casp8(-/-)Ml
154 esized that children would be more likely to
die during the period several months before their mother
155 .51, p=<.05), if the patient was expected to
die during the shift (F(1,155)=89.67, p=<.01) and if the
156 0 neurons are added each breeding season and
die during the subsequent nonbreeding season.
157 or were admitted to a nursing home and 9.7%
died during the 1-year follow-up period.
158 eight-hundred eighty-three patients (19.4%)
died during the 1-year follow-up period.
159 45 patients
died during the 10-year follow-up.
160 bits between 1998 and 2000, a total of 3,251
died during the 13-year follow-up.
161 fection, mainly those born during 1945-1964,
died during the 2006-2010 five-year period.
162 174 participants
died during the 23 years of follow-up (121 in the interv
163 Three patients (13%)
died during the 30 day follow-up.
164 Fourteen percent of subjects
died during the 30-day follow-up period.
165 3909 of the 49,731 D:A:D study participants
died during the 308,719 person-years of follow-up (crude
166 e of the tsunami and an additional 95 people
died during the 38-month follow-up period.
167 ients who underwent randomization, 1 patient
died during the 5-year follow-up period; 134 of the rema
168 nts did not provide follow-up data: 21 (24%)
died during the 6-month follow-up period, and 17 (19%) d
169 participants, 659 (ELSA) and 638 (SIGa-Bage)
died during the 9-year follow-up.
170 Four patients (9%)
died during the acute disease, but most showed marked im
171 937 person-years of observation), 110 (1.1%)
died during the average follow-up of 9.7 years.
172 % of people in the lowest wellbeing quartile
died during the average follow-up period of 8.5 years co
173 ts (16%) randomized to frequent hemodialysis
died during the combined trial and post-trial observatio
174 11 patients
died during the core 12-month treatment phase or up to 5
175 d deaths were recorded but 16 (62%) patients
died during the course of follow-up.
176 Two patients
died during the course of the trial, one each from laryn
177 g the night, with no change in subjects that
died during the day.
178 influenza in 1918-19 killed more people than
died during the entire war, showing how much remained be
179 Two patients
died during the event, neither of whom had known valve i
180 ority of larvae injected with, or fed, dsRNA
died during the final larval stage prior to pupation.
181 atients treated in designated trauma centers
died during the first 24 hours of hospitalization.
182 Infants who had major congenital anomalies,
died during the first 3 days of life, or had missing dat
183 The patients who
died during the first 48 hours after venoarterial extrac
184 ty was 30% (176 patients); 76 patients (13%)
died during the first 48 hours.
185 ts of 583 and 239 females whose male co-twin
died during the first postnatal year and first 28 days o
186 d to participate (3 patients), and those who
died during the first year (35 patients).
187 summary score within the highest percentile
died during the first year of follow-up, indicating prom
188 Fifty-six patients assigned to TX/CEX
died during the follow-up compared with 75 of patients a
189 SD and seven (0.2%) of 4074 matched controls
died during the follow-up period (HR 2.78, 95% CI 0.95-8
190 After censoring cases in which patients
died during the follow-up period and adjusting for month
191 Eighteen patients (64%)
died during the follow-up period ranging from 6 to 230 m
192 Forty-six percent of the cases
died during the follow-up period, compared with 13.0% of
193 ere readmitted at least once while 22 (7.9%)
died during the follow-up period.
194 d pulmonary diffusion abnormalities, and 25%
died during the follow-up period.
195 732(29.87%) of patients
died during the follow-up.
196 f the 547 lung cancer patients, 412 patients
died during the follow-up.
197 articipants in the general population sample
died during the follow-up.
198 Four patients
died during the full follow-up, two of breast cancer-rel
199 METHODS/Ninety-one patients
died during the hospital stay while 92 patients from the
200 ging was performed in 36 patients (1 patient
died during the hospital stay).
201 to the intensive care unit, and 30 patients
died during the hospital stay.
202 of patients, and nearly half of the patients
died during the hospitalization period.
203 mechanical support successfully, but 6 (29%)
died during the index admission from persistent cardioge
204 escents who did not have their sex recorded,
died during the index admission, had no valid discharge
205 s Hospital from 1995 through 2018, 14 (8.2%)
died during the index episode and 19 were observed for l
206 Fourteen patients (0.1%)
died during the index hospitalization and were excluded
207 Those who
died during the index hospitalization or who had an addi
208 Of 416,997 patients, 3.8%
died during the initial SNF stay, 28.6% required readmis
209 ypertension were identified, and 23 patients
died during the mean follow-up of 32+/-14 months.
210 12,123 children included for analysis, 1600
died during the median follow-up of 7.1 years.
211 or decompensated cirrhosis, 61% (504 of 830)
died during the median follow-up period of 2.26 years.
212 se transcripts is only seen in subjects that
died during the night, with no change in subjects that d
213 Two varenicline-group participants
died during the nontreatment phase.
214 ine participants in the slowest HRR quartile
died during the observation period compared with 14 part
215 Nineteen patients
died during the observation period.
216 hildren aged </= 5 y who commenced chelation
died during the period studied, with lead poisoning a pr
217 % had coronary artery bypass surgery, and 3%
died during the readmission.
218 Of the remaining 24, 3 (13%)
died during the same hospitalization.
219 han the 315 (9.0%) matched noncaregivers who
died during the same period.
220 Ten women
died during the study (0.61% per year).
221 41 (7%) treated patients
died during the study (15 [7%], 15 [7%], 11 [5%]); the m
222 Two (3%) patients in the 30 mg group
died during the study (pulmonary artery thrombosis and c
223 Ten patients
died during the study (six [7%] in the high-titre group
224 Three patients
died during the study (two because of disease progressio
225 No patients
died during the study as a result of toxic effects.
226 One patient in the opicinumab 30 mg/kg group
died during the study due to a traffic accident, which w
227 11 participants
died during the study follow-up period (six in the 9vHPV
228 ears, the survival rate was 97%; one patient
died during the study from a nonhematologic cause.
229 Four patients
died during the study from fatal adverse events judged t
230 lepsy admitted to each unit who subsequently
died during the study period (April 1, 2009, to March 31
231 yoclonus were variable, with one patient who
died during the study period and five who were successfu
232 In total, 2137 (27%) patients
died during the study period with higher mortality rates
233 In total, 2137 (27%) patients
died during the study period with higher mortality rates
234 Two patients
died during the study period, 1 in each treatment group.
235 specialist nurses, 134 (7%) of 1795 patients
died during the study period, 88 (5%) of whom died after
236 22 (46%) patients
died during the study period, all from metastatic renal-
237 reatment, they had immigrated, emigrated, or
died during the study period, or because they were admin
238 None of the infants
died during the study period.
239 s in 3-mo intervals, and 246 (4.3%) children
died during the study period.
240 Thirty-four (46.6%) patients
died during the study period.
241 A total of 47 patients (55.3%)
died during the study period.
242 A total of 625 patients (35%)
died during the study period.
243 n=68) with ALS were recruited, of which 119
died during the study period.
244 otal of 8655(4.6%) were identified as having
died during the study period.
245 ted endophthalmitis or metastatic disease or
died during the study window.
246 the cause of death in over 40% of those who
died during the study, and the mortality increased marke
247 22 patients
died during the study, and three deaths were related to
248 Seven (7%) patients
died during the study, but none of the deaths was drug r
249 Three patients
died during the study, but the deaths were not deemed to
250 Three patients
died during the study, from causes judged unrelated to a
251 Overall, 71 (49%) patients
died during the study, most frequently because of diseas
252 93 patients (3% of the full analysis set)
died during the study, of which one death (in the denosu
253 nts with evaluable images, 68 patients (38%)
died during the study, were autopsied, and had neuritic
254 No patients
died during the study.
255 and 29 (6%) in the heparin-impregnated group
died during the study.
256 One patient in each group
died during the study.
257 Two patients
died during the study.
258 Six patients (all from the M+ group)
died during the study.
259 major bleeding was recorded, and no patient
died during the study.
260 11 (12%) of 95 patients
died during the study: eight with relapsed or refractory
261 23 (31%) patients
died during the study; none of these deaths were deemed
262 Three patients
died during the study; none of these deaths were judged
263 rsing homes, we identified all residents who
died during the three months prior to measurements.
264 eight individuals (7.3%; 95% CI, 4.9%-10.4%)
died during the training period; all deaths were related
265 d five (4%) of 113 in the chemotherapy group
died during the treatment period (from the day of the fi
266 A total of 62 patients
died during the trial (24 from Hodgkin's lymphoma), for
267 Eight (14%) of 57 patients
died during the trial due to disease progression.
268 123 (2%) people
died during the trial, 65 assigned vitamin D and 58 allo
269 Ten participants
died during the trial.
270 No patients
died during the trial.
271 No participants
died during the trial; 81 serious adverse events were re
272 edian MELD score 7.9 vs. 11.4), and only one
died during the trials.
273 ggesting that virus-infected individuals had
died during the winter.
274 IL-1beta was higher in patients who
died during the year after hospitalization (n = 52, 16.5
275 tal mortality rates (NMR; the probability of
dying during the first 28 days of life) for all countrie
276 lyses, type 2 patients had decreased odds of
dying during the hospitalization (0.47; 95% CI, 0.38-0.5
277 tay (median, 31 d vs 13 d; p < 0.01), and to
die during their hospital stay (34% vs 23%; odds ratio,
278 f suicide among persons who had a parent who
died during their childhood.
279 Five patients
died during their DAT infusion or soon afterwards, but n
280 18%) required ventilator support, and 2 (5%)
died during their hospital admission.
281 sion, 1 (3%) required a ventilator, and none
died during their hospital admission.
282 Twelve percent (n = 333)
died during their hospital stay, 8.1% (n = 222) of patie
283 Twenty-seven patients (26.0%)
died during their hospital stay, and 24 of them had posi
284 s at a tertiary care university hospital who
died during their hospitalization from 2005 to 2014.
285 Of the 229 patients who
died during their hospitalization, 149 (65.0%) had sepsi
286 l ventilation, 19% had shock, and 588 (3.1%)
died during their hospitalization.
287 hundred seventeen of 331 (35.3%) inpatients
died during their hospitalization.
288 he conventional oxygen therapy group (20.2%)
died during their ICU stay (absolute risk reduction [ARR
289 tio = 0.52) in 18 of 389 (4.6%) patients who
died during their in-hospital stay.
290 ravenous colistin for >3 consecutive days or
died during therapy (termed colistin cases).
291 Two status-1 patients
died during transplant surgery.
292 vs 94.9%, P < .0001) and were more likely to
die during treatment (18.9% vs 2.1%, P < .0001).
293 One patient
died during treatment (unknown cause), and 12 other pati
294 Five (2%) patients
died during treatment in each group.
295 16 (12%) patients
died during treatment or within 31 days of the last dose
296 Three (8%) patients
died during treatment, including one individual who died
297 Three of the patients
died during treatment.
298 Two participants, one in each group,
died during treatment; neither death was considered to b
299 al mortality were 57% (n = 41), 53% (n = 38)
died during venoarterial extracorporeal membrane oxygena
300 y of regions and species sampled, trees that
died during water shortages were less resilient to previ